Fredric Jaffe
Pulmonary Disease · Philadelphia, PANPI 1043234008
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $993, more than ten times the $52 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 54 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$209
- Harmony Biosciences LLC$196
- Insmed, Inc.$122
- Jazz Pharmaceuticals Inc.$98
- AstraZeneca$92
- Amgen$82
- plus $525 from 14 others
Across 3 payments — averaging $9203.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$14K
- Boehringer Ingelheim$14K
What the payments were for
- Food & beverage$1,324100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $209 |
| Harmony Biosciences LLC | 7 | $196 |
| Insmed, Inc. | 4 | $122 |
| Jazz Pharmaceuticals Inc. | 4 | $98 |
| AstraZeneca | 6 | $92 |
| Amgen | 4 | $82 |
| Mallinckrodt Hospital Products Inc. | 2 | $77 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 2 | $64 |
| Boehringer Ingelheim | 2 | $48 |
| Merck | 2 | $41 |
| Philips North America LLC | 2 | $35 |
| Baxter Healthcare | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Pulmonx Corporation | 1 | $22 |
| United Therapeutics Corporation | 1 | $22 |
| Resmed Corp | 1 | $19 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$1,324 in reported general payments places this provider in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,298 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,500 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $209 | $32,79850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.